公开(公告)号：EP1419770A4

公开(公告)日：2005-08-03

申请号：EP01958448

申请日：2001-08-24

申请人： SHIONOGI & CO

发明人： ISHIZUKA NATSUKI ,  NAGATA KIYOSHI ,  YAMAMORI TERUO ,  SAKAI KATSUNORI

IPC分类号： C07D249/06 ,  A61K31/341 ,  A61K31/351 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/4192 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4427 ,  A61K31/443 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5375 ,  A61K31/5377 ,  A61P3/06 ,  A61P9/10 ,  A61P43/00 ,  C07D207/32 ,  C07D207/34 ,  C07D207/50 ,  C07D231/12 ,  C07D231/14 ,  C07D233/56 ,  C07D249/08 ,  C07D249/10 ,  C07D249/12 ,  C07D257/04 ,  C07D261/08 ,  C07D263/32 ,  C07D271/06 ,  C07D271/10 ,  C07D271/107 ,  C07D277/22 ,  C07D277/24 ,  C07D285/06 ,  C07D285/08 ,  C07D285/10 ,  C07D285/12 ,  C07D285/135 ,  C07D307/36 ,  C07D307/38 ,  C07D307/42 ,  C07D307/68 ,  C07D333/06 ,  C07D333/12 ,  C07D333/16 ,  C07D333/18 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D405/04 ,  C07D405/14 ,  C07D407/04 ,  C07D409/04 ,  C07D409/14 ,  C07D413/04 ,  C07D413/06 ,  C07D413/14 ,  C07D417/04 ,  C07D417/10 ,  C07D417/14

CPC分类号： C07D231/12 ,  A61K31/351 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4025 ,  A61K31/41 ,  A61K31/415 ,  A61K31/4164 ,  A61K31/4178 ,  A61K31/42 ,  A61K31/421 ,  A61K31/422 ,  A61K31/425 ,  A61K31/426 ,  A61K31/427 ,  A61K31/433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5377 ,  C07D271/06 ,  C07D271/107 ,  C07D277/24 ,  C07D405/04 ,  C07D413/04 ,  C07D413/06 ,  C07D417/04

摘要： A medicinal composition having apo AI expression accelerating action, which comprises a compound represented by the formula (I): (I) wherein Y1 represents O, S or NR1, Y2, Y3, Y4 and Y5 represent CR2 or N, CR3 or N, CR4 or N, and CR5 or N, respectively, R1 represents A1, -Z-A2, hydrogen, a lower alkyl or the like, R2, R3, R4 and R5 represent A1, -Z-A2, hydrogen, a halogen or the like, -Z- represents a single bond, -CR6=CR7- or the like, R6 and R7 are hydrogen or a lower alkyl, and A1 and A2 are an aryl, a heterocyclic group or the like, or the like.

公开(公告)号：EP1806342A4

公开(公告)日：2010-02-17

申请号：EP05800158

申请日：2005-10-28

申请人： SHIONOGI & CO

发明人： ISHIZUKA NATSUKI ,  SASATANI TAKASHI ,  HIRAMATSU YOSHIHARU ,  INAGAKI MASANAO ,  ODAN MASAHIDE ,  HASHIZUME HIROSHI ,  MITSUMORI SUSUMU ,  FUJII YASUHIKO ,  FUKUI YOSHIKAZU ,  WATANABE HIDEAKI ,  SATO JUN

IPC分类号： C07D213/82

CPC分类号： C07D213/82

公开(公告)号：EP1916245A4

公开(公告)日：2009-10-28

申请号：EP06781305

申请日：2006-07-20

申请人： SHIONOGI & CO

发明人： KUGIMIYA AKIRA ,  SHICHIJO MICHITAKA ,  HIRAMATSU YOSHIHARU ,  ISHIZUKA NATSUKI

IPC分类号： C07D401/04 ,  A61K31/404 ,  A61K31/4439 ,  A61K31/454 ,  A61P11/06 ,  A61P37/08 ,  A61P43/00 ,  C07D401/14 ,  C07D403/04

CPC分类号： C07D403/04 ,  C07D401/04 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D417/14

公开(公告)号：EP1690538A4

公开(公告)日：2009-02-25

申请号：EP04819801

申请日：2004-11-29

申请人： SHIONOGI & CO

发明人： FUKUI YOSHIKAZU ,  SASATANI TAKASHI ,  MATSUMURA KEN-ICHI ,  ISHIZUKA NATSUKI ,  YANO TOSHISADA ,  KANDA YASUHIKO ,  CHOMEI NOBUO

IPC分类号： C07D261/08 ,  A61K31/42 ,  A61K31/423 ,  A61K31/4245 ,  A61K31/427 ,  A61K31/428 ,  A61K31/435 ,  A61K31/4427 ,  A61K31/501 ,  A61K31/502 ,  A61K31/506 ,  A61K31/536 ,  A61K31/5377 ,  A61K31/5395 ,  A61P1/04 ,  A61P1/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P9/10 ,  A61P9/12 ,  A61P15/00 ,  A61P17/04 ,  A61P17/06 ,  A61P19/02 ,  A61P19/10 ,  A61P25/16 ,  A61P25/28 ,  A61P29/00 ,  A61P35/00 ,  A61P37/08 ,  A61P43/00 ,  C07D261/18 ,  C07D261/20 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12 ,  C07D417/12

CPC分类号： C07D417/12 ,  C07D261/08 ,  C07D261/18 ,  C07D413/04 ,  C07D413/06 ,  C07D413/12

摘要： Compounds represented by the formula (I):[wherein R1 to R10 each independently is hydrogen, halogeno, optionally substituted lower alkyl, etc.; X1 is -O-, -S-, -NR11- (wherein R11 is hydrogen, lower alkyl, etc.), -CR12R13CO-, -(CR12R13)mO-, or -O(CR12R13)m- (wherein R12 and R13 each independently is hydrogen or lower alkyl and m is an integer of 1 to 3), etc.; X2 is a single bond, -O-, -S-, -NR14- (wherein R14 is hydrogen, lower alkyl, etc., provided that R14 may be bonded to R6 to form a ring in cooperation with the adjacent atoms), or -CR15R16- (wherein R15 and R16 each independently is hydrogen or lower alkyl, provided that R15 may be bonded to R6 or R10 to form a ring in cooperation with the adjacent carbon atoms and R16 and R9 in combination may form a bond); and X3 is COOR17, C(=NR17)NR18OR19, etc.], pharmaceutically acceptable salts of the compounds, or solvates of any of these.

公开(公告)号：EP1426046A4

公开(公告)日：2005-11-02

申请号：EP01967683

申请日：2001-09-14

申请人： SHIONOGI & CO

发明人： ISHIZUKA NATSUKI ,  SAKAI KATSUNORI ,  HAYASHI KUNIO

IPC分类号： A61K31/15 ,  A61K31/155 ,  A61K31/357 ,  A61K31/40 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/498 ,  A61K31/50 ,  A61K31/502 ,  A61K31/505 ,  A61K31/53 ,  A61P3/06 ,  A61P9/10 ,  C07D213/16 ,  C07D213/30 ,  C07D213/40 ,  C07D213/64 ,  C07D215/04 ,  C07D237/08 ,  C07D237/12 ,  C07D237/14 ,  C07D239/26 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D251/30 ,  C07D257/04 ,  C07D277/22 ,  C07D277/24 ,  C07D319/20 ,  C07D401/10 ,  C07D405/10 ,  C07D409/04 ,  C07D409/10 ,  C07C259/14

CPC分类号： C07D213/06 ,  A61K31/15 ,  A61K31/155 ,  A61K31/357 ,  A61K31/40 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/47 ,  A61K31/495 ,  A61K31/4965 ,  A61K31/498 ,  A61K31/50 ,  A61K31/502 ,  A61K31/505 ,  A61K31/53 ,  C07D213/16 ,  C07D213/30 ,  C07D213/40 ,  C07D213/64 ,  C07D215/04 ,  C07D237/08 ,  C07D237/12 ,  C07D237/14 ,  C07D239/26 ,  C07D239/52 ,  C07D241/12 ,  C07D241/42 ,  C07D251/30 ,  C07D257/04 ,  C07D277/22 ,  C07D277/24 ,  C07D319/20 ,  C07D401/10 ,  C07D405/10 ,  C07D409/04 ,  C07D409/10

摘要： A medicinal composition which exasperates apo AI expression as a remedy for circulatory diseases based on the HDL function enhancement. It is an apo AI expression accelerator which contains a compound represented by the formula (I), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a solvate of these: (I) wherein X1 and X2 each independently is optionally substituted aryl or heteroaryl, hydrogen, halogeno, etc.; ring A is a benzene ring or six-membered aromatic heterocycle containing one to three nitrogen atoms, the rings each being optionally fused with other aromatic ring, and R1 to R4 each independently is hydrogen, halogeno, lower alkyl, lower alkoxy, etc.

公开(公告)号：EP0924207A4

公开(公告)日：2001-06-13

申请号：EP97935855

申请日：1997-08-22

申请人： SHIONOGI & CO

发明人： ISHIZUKA NATSUKI ,  MATSUMURA KEN-ICHI ,  SAKAI KATSUNORI ,  KONOIKE TOSHIRO ,  YORIFUJI TADAHIKO ,  HARA SEIJIRO ,  MATSUO YOSHIYUKI

IPC分类号： C07D311/22 ,  C07D311/60 ,  C07D407/04 ,  C07D407/14 ,  C07D409/04 ,  C07D409/14 ,  C07D311/58 ,  C07D311/64 ,  C07D311/68 ,  C07D335/06 ,  C07D407/12 ,  A61K31/352

CPC分类号： C07D407/04 ,  C07D311/60 ,  C07D407/14 ,  C07D409/04 ,  C07D409/14

摘要： Compounds represented by general formula (I), pharmaceutically acceptable salts thereof, and hydrates of the same; and medicinal compositions such as endothelin receptor antagonists, remedies for peripheral circulatory insufficiency or macrophage foaming inhibitors containing these compounds. In said formula (I), R?1, R2, R3 and R4¿ independently represent each hydrogen, optionally substituted alkyl, hydroxy, optionally substituted alkoxy, etc.; R5 represents optionally substituted alkyl, optionally substituted aryl, optionally substituted heterocycle, etc.; R6 represents hydrogen, optionally substituted alkyl, etc.; R7 represents hydrogen, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted aryl, optionally substituted heterocycle, etc.; A represents S or O; and the broken line means the presence or absence of a bond.